Maetzold Derek J's Form 4 filing
Castle Biosciences Inc (CSTL) · filed Dec 20, 2023
- Accession no.
- 0001447362-23-000188
- Filed
- Dec 20, 2023
- Trade date
- Dec 18-19, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 14 non-derivative transactions. Open-market sales total $334.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maetzold Derek JCIK 0001239501 | Director, Officer (Pres. & Chief Exec. Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 18, 2023 | Common Stock | SSaleDisposed | −5,720 | $20.27F2 | −$115,944.4 | 108,437 | Direct | |
| Dec 18, 2023 | Common Stock | SSaleDisposed | −433 | $20.27F2 | −$8,776.91 | 94,617 | Indirect | |
| Dec 18, 2023 | Common Stock | SSaleDisposed | −433 | $20.27F2 | −$8,776.91 | 83,512 | Indirect | |
| Dec 18, 2023 | Common Stock | SSaleDisposed | −158 | $20.27F2 | −$3,202.66 | 12,559 | Indirect | |
| Dec 18, 2023 | Common Stock | SSaleDisposed | −158 | $20.27F2 | −$3,202.66 | 12,558 | Indirect | |
| Dec 18, 2023 | Common Stock | SSaleDisposed | −158 | $20.27F2 | −$3,202.66 | 12,558 | Indirect | |
| Dec 18, 2023 | Common Stock | SSaleDisposed | −158 | $20.27F2 | −$3,202.66 | 12,552 | Indirect | |
| Dec 19, 2023 | Common Stock | SSaleDisposed | −5,719 | $20.84F9 | −$119,183.96 | 102,718 | Direct | |
| Dec 19, 2023 | Common Stock | SSaleDisposed | −958 | $20.84F9 | −$19,964.72 | 93,659 | Indirect | |
| Dec 19, 2023 | Common Stock | SSaleDisposed | −958 | $20.84F9 | −$19,964.72 | 82,554 | Indirect | |
| Dec 19, 2023 | Common Stock | SSaleDisposed | −348 | $20.84F9 | −$7,252.32 | 12,211 | Indirect | |
| Dec 19, 2023 | Common Stock | SSaleDisposed | −350 | $20.84F9 | −$7,294 | 12,208 | Indirect | |
| Dec 19, 2023 | Common Stock | SSaleDisposed | −350 | $20.84F9 | −$7,294 | 12,208 | Indirect | |
| Dec 19, 2023 | Common Stock | SSaleDisposed | −350 | $20.84F9 | −$7,294 | 12,202 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $20.140 to $20.605, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 7 transactions in Table I.
- F9
This transaction was executed in multiple trades at prices ranging from $20.390 to $21.160, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 7 transactions in Table I.